GLPwatch
The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.
Diabetes Res Clin Pract · 2016
Last updated 2026-05-28In a mouse study, the weight-loss effect of liraglutide, a GLP-1 drug, did not depend on the brain’s leptin, serotonin, or two specific appetite-regulating pathways (POMC and CART). However, a possible link to reduced activity in a different pathway (orexin) was observed.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2016 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 0.33 |
| NIH percentile | 20 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, did not require functional leptin receptor, serotonin, and hypothalamic proopiomelanocortin and cocaine amphetamine regulated transcript activities in mice, although decrease in functional hypothalamic orexin activity might be involved in the acute anorexic effect of liraglutide.
Verbatim abstract via PubMed 27585115 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.